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Abstract
Nicastrin is an obligatory component of the c-secretase; the enzyme complex that leads to the production of Ab fragments
critically central to the pathogenesis of Alzheimer’s disease (AD). Analyses of the effects of common variation in this gene on
risk for late onset AD have been inconclusive. We investigated the effect of rare variation in the coding regions of the
Nicastrin gene in a cohort of AD patients and matched controls using an innovative pooling approach and next generation
sequencing. Five SNPs were identified and validated by individual genotyping from 311 cases and 360 controls. Association
analysis identified a non-synonymous rare SNP (N417Y) with a statistically higher frequency in cases compared to controls in
the Greek population (OR 3.994, CI 1.105–14.439, p = 0.035). This finding warrants further investigation in a larger cohort and
adds weight to the hypothesis that rare variation explains some of genetic heritability still to be identified in Alzheimer’s
disease.
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Introduction
Alzheimer’s disease (AD) is the commonest neurodegenerative
disease of the elderly and with an increasingly aging population in
many countries the burden of disease will continue to rise
inexorably. Until recently, the e4 allele of the APOE gene was the
only well established genetic risk factor for the typical late-onset
form of the disease. However, recent results from two of the largest
genome wide association studies have identified and replicated
several novel loci with high significance [1,2]. These loci include
clusterin (CLU) and complement receptor 1 (CR1). In contrast to
the APOE locus, the effect size and attributable risk for these
variants are more modest. For example the CR1 locus has odds
ratios of 1.11 and attributable fractions of 3.8% compared to 25.5%
for APOE [2]. It is clear from these studies that in common with
other complex disorders such as Type II diabetes or physiological
traits such as height that susceptibility genes detected by whole
genome association studies for AD are common (MAF.0.1) and of
modest effect (RR,1.3, with APOE being a notable exception).
Cumulatively these variants only explain a small proportion of the
genetic risk; additional risk will undoubtedly be explained by more
common variants of small effect. However, it is increasingly
recognised that rare variants have a role in complex disease. An
example in neurodegenerative disease is the glucocerebrosidase
gene (GBA) in Parkinson’s disease, individuals homozygous for
mutations in this gene present with theMendelian disorder Gaucher
disease, while individuals heterozygous for the same mutations have
an increased risk for Parkinson disease [3,4] The cumulative
frequency of GBA mutations in Parkinson disease cases can be as
high as 9.0% compared to less than 0.5% in controls. Such variants
are not included on commercial genotyping arrays but are only
detected through re-sequencing approaches.
While genome wide association studies are appropriately
powered to detect common variants of modest effect, linkage
studies are more effective in detecting rare variants of larger effect
even in the presence of allelic heterogeneity. Linkage studies in AD
may therefore indicate loci harbouring rare variants and nominate
candidate genes for re-sequencing. In a meta-analysis of AD
linkage studies by Butler et al, 2009 [5], although there were no
genome wide significant findings, three regions showed genome
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wide suggestive evidence for linkage. The gene for Nicastrin, one
of the components of the c-secretase is underneath one of the
suggestive linkage peaks on chromosome 1.
Intramembranous c-secretase cleavage of the amyloid precursor
protein (APP) is the final step in the production of the amyloid-b
peptide (Ab); the main constituent of amyloid plaques found in the
brains of patients with Alzheimer’s disease [6]. The length of the
Ab peptide is dependent on the c-secretase cleavage site, with
Ab42 being the most amyloidogenic peptide. Mutations in another
component of the c-secretase, presenilin 1 (PS1) are found in the
early onset autosomal dominant form of Alzheimer’s disease [7,8].
Nicastrin was first identified by immunoprecipitation of PS1
followed by analysis by mass spectrometry and it acts as the
substrate binding component of the c-secretase complex [9].
Several studies have investigated the role of common SNPs in the
Nicastrin gene on risk of AD. Haplotype studies have identified a
haplotype (HapB) associated with early onset AD in people who lack
the APOE e4 risk variant in a Dutch population based sample [10].
This association was replicated in a Sardinian study containing both
familial and sporadic AD cases, but failed to be significantly
replicated in others [11,12]. A study looking at normative cognitive
aging found an effect of HapB on life long stable cognitive ability,
but not on age related cognitive change [13]. There have also been
investigations of the effect of Nicastrin promoter SNPs but again
with varying results in different populations [13–16].
Systematic screens for rare variants that may have an effect on
protein function have been carried out using small sample sizes
comprising mostly familial AD cases. Dermaut et al (2002) [10]
screened 78 familial and 38 sporadic cases using DHPLC indentifying
4 SNPs in the coding regions. One of which caused an amino acid
substitution (N to Y at codon 417). Confalaoni et al (2003) [17] also
identified this as the only missense mutation, present in 1 of 104
familial cases, 2 of 174 sporadic cases and one of 191 controls (although
a young control). These studies use a combination of familial and
sporadic AD cases which may have a heterogeneous genetic aetiology.
In addition non-sense and truncating mutations in the genes of
the c-secretase complex, including Nicastrin have recently been
implicated in Familial Acne Inversa and haploinsufficency was
inferred to be causal. None of the mutations have previously been
shown to cause early onset AD, but it may be that these could
contribute to risk of late onset AD [18].
To investigate the effect of rare variation in a larger sample size of
sporadic AD patients we have re-sequenced the coding regions of the
Nicastrin gene in a cohort of AD patients and matched controls using
an innovative pooling approach and next generation sequencing.
Results
Genomic DNA from 311 Alzheimer’s patients and 360 controls
were combined to create case and control pools. Nicastrin exon
regions were amplified using 16 exon-specific PCR reactions, and
then PCR products were pooled in equimolar amounts and
subjected to deep sequencing.
The sequencing of the case and control pools generated 307005
and 302171 reads respectively. For the case and control pools
87.1% and 87.0% of reads respectively mapped to the reference
sequence. This resulted in a mean coverage of 228 reads per
position for each individual in the case pool (114 per allele) and
197 reads per position for each individual in the control pool (98
reads per allele). Fig. 1A shows the distribution of read coverage.
Using the cut off for variant calling described in the methods we
were able to identify SNPs at a frequency of 3–8 variants in the
pool, depending on the transition type. For example in the case
pool the error distribution allowed the identification of a G-A
transversion with a frequency of 3 variants, but for a A-C
transition the error distribution was higher only allowing the
identification of variants with a frequency as low as 7.
Table 1 shows the identified variants and those which were
individually genotyped using Sequenom genotyping, for the
purpose of validation. These included all common SNPs, all
non-synonymous SNPs and a selection of the remaining rare SNPs
identified. The SNPs at positions 158585487 and 158594972 had
a frequency below the cut off for variant calling, but these were
investigated in addition to the called SNPs (SNP 158585487 if
validated would cause a non-synonymous change that would be
potentially damaging, and SNP 158594972 is at a very high
frequency only in one read direction). The common SNP at
position 158587689 was not genotyped as it is known to be in
perfect LD with the genotyped SNP at position 158588123 [17].
Five SNPs identified in the sequencing were validated by
individual genotyping. In addition the two SNPs that did not pass
the acceptable threshold that were genotyped were not validated.
These are likely to be due to sequencing or alignment errors. Most
of the SNPs with a minor allele frequency below 0.01 were false
positive although two rare variants were validated at a low
frequency. Of the common variants identified only the SNP at
position 158588123 was validated, which also validates the SNP at
position 158587689. Three SNPs that had relatively high MAF
(0.03–0.1) were not validated in the single genotyping. On closer
inspection it can be seen that these SNPs have an extremely high
forward to reverse read ratio, being overly represented in the
forward reads possibly indicative of a sequencing artefact. The
level of discrepancy between forward and reverse reads was
represented using a score which was calculated from the absolute
difference between the frequencies in the forward and reverse
reads divided by the mean frequency (table 1).
The allele frequencies for validated SNPs were compared
between SNPs with a F:R read ratio score of 1 or lower (fig. 2).
The correlation between the Sequencing in pools and the individual
genotyping is 0.82 and 0.95 for case and control respectively. If the
outlier (SNP at position 158592193 which is in 32 bp from the start
of the PCR product and in a relatively low depth region) is excluded
the correlation becomes stronger, 0.98 for cases and 1 for controls.
Association analysis was carried out on the variants validated by
individual genotyping (table 2). No association with AD was
identified for the common SNP at position 158588123. This is
located in exon 10 and results in a synonymous change. Of the
rare variants identified, two resulted in non-synonymous amino
acid changes. Both were predicted to be possibly damaging using
POLYPHEN [19] and have a higher frequency in cases compared
to controls, with the association of the SNP at position 158590601
reaching statistical significance (OR=4.475, CI = 1.24–16.12,
Chi2 = 6.28, p = 0.012). No association was found with age of
onset (data not shown). This significantly associated rare SNP was
genotyped in additional samples by individual genotyping. In total
2016 samples were genotyped comprising AD and control
individuals as shown in table 3. There is a much smaller effect
size in the UK population which had a lower MAF, where the
association would not reach statistical significance alone. There
was no association identified in the remaining samples from other
Western European populations. Overall there was a weakly
significant effect in a Meta-analysis of all the samples studied
(table 3, using random effects model z = 1.98, p= 0.048).
Discussion
We demonstrate along with other recent publications [20–22]
that it is possible to use pooled samples to screen for rare SNPs in
Nicastrin Risk Variants for Alzheimer’s Disease
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large pools and after quality control obtain reliable allele
frequency data. Although the cost of next-generation sequencing
is reducing, it is still expensive and time consuming to resequence
large numbers of individuals. This technique makes the large
sample sizes required to have enough power to detect association
more affordable.
In studies with a high depth of coverage it is the sequencing
error rate (both sequencing and PCR errors) that is the limiting
factor in the identification of very rare variants. An inadequacy in
this study is that a single heterozygote SNP in one individual in the
pool would have an allele frequency below that of some
sequencing errors. We were able to identify variants as low as
one individual in the pool, but we cannot rule out that some true
variants have not been identified. A reduction in pool size could
insure that the lowest frequency SNP would have an allele
frequency above that of the distribution of sequencing error.
Limitations to the pooling approach are difficulties in ensuring
equimolar representations of samples. In this study careful
quantification of individual DNA samples and accurate combin-
ing has provided accurate allele calling, as shown by the strong
correlation of allele frequencies obtained with pooled sequencing
compared to individual genotyping. Increased accuracy in sample
representation, and allele frequency estimation may have been
achieved by performing separate PCR reactions in each
individual and pooling of PCR products [22], although this
would have resulted in increased costs and DNA use. A limitation
of the use of pools is the loss of individual genotype data. For
example one cannot test for an association under different
models, or look at gene-gene or gene-environment interactions.
An alternative approach gaining popularity is the use indexed
libraries [3,23,24] and combinational pooling strategies [25,26].
Although at present there are limitations to the number of
samples that can feasibly be pooled, taking into account the cost
and time constraints of preparing a library for each sample. We
have shown that pooling before library generation without
indexing is a viable alternative, saving cost and time and allowing
the pooling of many more individuals, which is an especially
useful way of screening large numbers of samples in a relatively
small region. With recent improvements in read length, and
sequence output as well as improving allele calling algorithms
especially designed for pooled analysis the capacity of this
technique is growing [27–30].
Out of 16 SNPs identified from pooled sequencing 11 were
genotyped in individual samples and of these six were validated.
There was an excellent correlation between the sequencing and
individual genotyping results, but only for samples that had a
forward to reverse read ratio score of less that 1. This indicates
that the DNA pooling step was very accurate, but because of bias
introduced in the sequencing (most likely at the PCR amplifica-
tion stages) single genotyping validation is required for all but
allele frequencies passing the most stringent quality control
thresholds.
There are no common SNPs previously identified in Caucasian
individuals in the regions sequenced as listed in dbSNP (build 130).
The regions were investigated in the publically available SNP
call data from the pilot 1000 genomes project data (www.
1000genomes.org). Pilot 1 contains low depth whole genome
sequencing of 60 individuals. Pilot 3 contains high depth
sequencing of around 1000 gene regions in which the regions
studied here are represented. The only SNPs that were identified
Figure 1. Depth of coverage. A: The depth of coverage at each position where the X axis shows the genomic position on chromosome 1 (hg18,
Mar. 2006). B: Locations of the PCR products aligned to the X axis. C: Locations of the Exons of Nicastrin aligned to the X axis.
doi:10.1371/journal.pone.0017298.g001
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in both the 1000 genomes data and our data are the SNPs at
positions 158588123 and 158587689 which both have a minor
allele frequency of 0.035 in the case pool and 0.048 in the control
pool. In both pilot 1 and pilot 3 these SNPs have an allele
frequency of 0.04. No other SNP above a frequency of 0.01 was
identified in the 1000 genome data which were not identified in
our sample. This is encouraging as it suggests that any SNP of a
reasonable frequency had been detected. It is as expected that very
rare SNPs identified are likely to be population specific.
Association analysis was carried out on the identified variants.
There was no significant effect of the more common variants (at
positions 158588123 and 158587689). The rare variants were also
tested for association although in this sample size there is limited
power to detect an association of variants with low MAF. The two
nonsynonomous SNPs were found to be over represented in the case
pool compared to the control pool with the N417Y variant reaching a
level of statistical significance. The N417Y residue is located in the
ectodomain of the protein. Examination of residues 261–502 reveal
sequence similarity to the peptidase family [31]. The region has been
shown to act as a recognition site for c-secretase with the major
substrate recognition site consisting of Glu333 and its nearby residues.
Although it is conceivable that sequences outside residues 312–340
may contribute to substrate binding [31]. Deep alignment of
mammalian species shows little conservation at this residue, but this
particular amino acid change is not seen in any other species
suggesting it may not be well tolerated. The substitution remains as a
non-charged polar amino acid, but the change results in a large size
difference. It is also a putative glycosylation site, suggesting there is
still potential for an effect on the protein function. This variant has
been previously identified in two genetic screens. Dermaut et al [10]
identified the substitution in one individual from a screen of 78 Dutch
Familial early onset AD cases (FAD). A follow up in a larger number
of 354 FAD and 475 controls of Italian origin found an equal
frequency in both. Additionally Confaloni et al [17] screened 174
sporadic AD patients and found two individuals carrying this
mutation. It was also identified in one out of 191 controls (although
a relatively young control), therefore showing a similar allele
frequency as in our case and control groups. Functional analysis
has been carried out on the substitution N417Y [10]. Ab40 and Ab42
levels were measured in conditioned media of HEK-293 cells
transfected with the mutant and wild-type Nicastrin cDNA. Results
were compared with known clinical mutations that cause FAD.
Unlike the effects of the causal FADmutations Ab40 and Ab42 levels
were similar for N417Y and wild type NCSTN. These results do not
disprove a functional effect of the substitution as it may be that the
effect is modest or only apparent in vivo. The SNP was genotyped in
a larger sample size of sporadic AD and control individuals (table 3).
No significant effect was seen in these populations, but in a meta
analysis including the Greek samples there is a significant association.
As with many rare variants there is likely to be population
heterogeneity, in terms of different allele frequencies, and different
genetic background between populations.
In conclusion we have screened the coding regions of the
Nicastrin gene and identified rare variation. We did not
Table 1. Identified variants indicating the frequency in the pool and the individual genotyping results where carried out.
Position
(hg18, Mar.
2006)
Reference
Base
Base
Change
Amino
Acid
Change Sequencing Results
Individual Genotyping
Results
Case Pool Control Pool
Case
Freq (N)
Control
Freq (N)
Freq Depth
F:R ratio
score* Freq Depth
F:R ratio
score*
158579744 T G 0.011 43865 0.06 0.012 53337 0.35 0.000 (290) 0.000 (343)
158579822 A G 4A.A 0.008 29914 0.75 0 37900 Not present
158579842 A G 11D.G 0.034 32766 1.09 0.033 40522 1.05 0.000 (290) 0.000 (342)
158585459 G A 79E.E 0.015 49008 0.41 0 77896 Not present
158585487 G T** 89G.C 0.009 62187 0.10 0.009 96747 0.10 0.000 (290) 0.000 (345)
158587689 A G 212L.L 0.038 68900 0.10 0.054 72522 0.19
158588079 G A 0.006 24984 0.54 0 59781 Not present
158588123 C T 249D.D 0.033 28255 0.32 0.054 67365 0.40 0.035 (276) 0.048 (344)
158588214 A T 280T.S 0.006 23823 1.68 0.006 54929 0.14 0.000 (282) 0.000 (339)
158588214 A C 280T.P 0.093 23823 1.68 0.100 54929 0.14 0.002 (280) 0.000 (341)
158590601 A T 417N.Y 0.012 33904 0.77 0 41705 Not present 0.019 (287) 0.004 (345)
158592193 T G 0.016 49363 0.14 0.017 91556 0.22 0.002 (288) 0.000 (345)
158592559 T C 0.013 61645 0.44 0.014 119627 0.42 0.000 (290) 0.000 (343)
158593669 T G 0.009 51485 0.37 0 66754 Not present
158594855 G C 0 61686 Not present 0.005 72880 0.42
158594885 A C 0.014 51872 0.95 0 60335 Not present 0.000 (290) 0.000 (343)
158594972 G T** 0.042 49352 1.56 0.051 58461 1.62 0.000 (288) 0.001 (345)
158594975 A C 0.026 47088 0.81 0.027 55505 0.83
158594975 A T 0 47088 Not present 0.012 55505 1.29198185
*The forward to reverse ratio score is the absolute difference between the frequencies in the forward and reverse reads divided by the mean frequency.
**indicates SNPs that did not pass the threshold for SNP calling but were still tested for validation.
doi:10.1371/journal.pone.0017298.t001
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identify any novel rare variants that are likely to have an effect
on the protein function. But we did find a modest association
with a previously identified non-synonymous SNP, although
this effect was not replicated in a larger sample size comprising
other European populations. The present study validates
the use of pooled DNA in the sequencing of small regions
of interest as a screening method for the identification of rare
SNPs.
Materials and Methods
Ethics Statement
Ethical approval for the main sample was obtained the Ethics
Committee of ‘‘George Papanicolaou’’ Hospital, Exohi Thessalo-
niki.
For the follow-up genotyping ethical approval was obtained
from the local ethics committee at each site. For the AddNeur-
omed project: Poland; the Ethics Committee of the Medical
University of Lodz, Finland; The Ethical Committee of Kuopio
University Hospital, Italy; Comitato Etico Aziende Sanitarie –
Umbria, and France; CPP Midi Pyrennees (Comite Protection des
Personnes). For the Medical Research Council Genetic Resource
for Late-onset AD samples ethical approval was obtained from
REC (Research Ethics Committee) for Wales. Informed consent
was obtained from all participants in writing. For Alzheimer’s
patients this consent was given by their next of kin or carer.
DNA Samples, Pooling and PCR
A cohort of Greek blood samples was collected from clinics at
Thessaloniki hospital (Aristotle University, Thessaloniki, Greece)
Figure 2. Comparison of allele frequencies for SNPs identified by sequencing and validated by individual genotyping. Only SNPs
with a ratio score of 1 or lower were considered (see text for details).
doi:10.1371/journal.pone.0017298.g002
Table 2. Association analysis for validated SNPs.
Position
(hg18, Mar. 2006)
Amino Acid
Change Case Control
chi square P value
(1 df)
N
Homozygous for
Minor Allele heterozygous N
homozygous for
Minor allele heterozygous
158588123 D249D 276 0 20 344 1 31 0.31
158588214 T280P 280 0 1 341 0 0 0.97
158590601 N417Y 287 0 11 345 0 3 0.012
158592193 288 0 1 345 0 0 0.96
158594972 288 0 0 345 0 1 0.84
doi:10.1371/journal.pone.0017298.t002
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from Caucasian patients and their carer (if unrelated i.e. husband/
wife for age matched control). Subjects were assessed using the
Mental State Examination (MMSE) [32] and diagnosed according
to the criteria of the National Institute of Neurological and
Communication Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Associations (NINCDS-ADRDA)
[33]. Controls were also recruited from the Greek blood donation
service. Local hospital ethical approval was obtained for all
samples collected.
Genomic DNA was extracted from whole blood using a
method based on an organic deproteinization reagent. Pools of
case and control DNA were constructed with quantification of
each sample using fluorometry in triplicate (using Quant-iT
PicoGreenH dsDNA kit (Invitrogen) and the fluroskan Ascent FL
fluorometer). All pipetting steps were carried out by hand with a
volume of 5 ml or greater to ensure accuracy. The two closest of
the three readings were selected and an average taken. The
concentration was only accepted if the difference between the two
readings was less than 5% of the average concentration. 311 AD
cases (with age of onset greater than 60 years) and 360 controls
were used to produce the pools. 16 oligonucleotides primer pairs
were designed to cover the 17 exons of the gene and the regions
amplified from the pooled DNA using standard PCR procedures
(table S1 contains the primer sequences). Reactions were carried
out in 50 ml volumes using 25 ng of pooled DNA for both cases
and controls. 2 ml of each PCR product was electrophoresed and
visualised using SYBR green (Roche). PCR product concentra-
tion was estimated by comparison of the level of fluorescence to a
serial dilution of Generuler DNA ladder (Fermentas Life
Sciences) using image J software [34]. The PCR products were
then combined in 2 case and control pools. The volume added
was adjusted according to the size of the PCR product ensuring
equal molar concentration.
Replication genotyping was performed using samples obtained
though AddNeuromed, a cross European, public/private consor-
tium developed for AD biomarker discovery [35] and a UK cohort
from the Medical Research Council Genetic Resource for Late-
onset AD [36].
Library preparation and sequencing
The PCR products were extracted using the QIAquick PCR
Purification Kit (Qiagen) as per manufactures’ instructions. End
repair was carried out using End-it DNA Kit (Cambio) to convert
the DNA ends to 59-phosphorylated blunt-end DNA. Extraction
was again carried out using the QIAquick PCR Purification Kit
and concatermerisation of the repaired PCR products was carried
out using the Quick Ligation kit (NEB). The samples were
fragmented by nebulisation from which a library was prepared
according to the Illumina protocol. The libraries were run on the
Illumina Genome Analyzer II for 36 cycles. The reference genome
used for sequence alignment was the Human Build 36.1 finished
human genome assembly (hg18, Mar. 2006). The images were
analyzed with the pipeline software (version 1.0, Illumina software)
to undertake base calling and sequence alignment to the reference
genome. The ELAND algorithm was used with the ‘ELAND
extended’ option.
Data Analysis
MAQ [37] was used to align the short read sequence data
obtained to a reference sequence using the default parameter of
only considering positions that have two or fewer mismatches in
the first 28 bp. For mismatches the maximum sum of mismatch-
ing bases quality score of 70 is used as a cut off for alignment.
The sequence alignment outputs were converted to a ‘‘pileup’’
format from which allele frequencies were elucidated. After
excluding the primer sequences the frequency of each substitution
was plotted as a histogram to access the distribution of errors. We
assumed an error model similar to that of Out et al, [22] where
errors occur at a constant proportion estimated by a Poisson
distribution and took the same conservative value of the error
rate. The 97.5% percentile of the observed distributions for each
base change was therefore taken as the cut off for variant calling.
Forward and reverse strands were considered separately and
variants were only considered if identified in both above the
threshold.
Statistical analysis was carried out using STATA.
Genotyping
Single nucleotide polymorphisms (SNPs) were genotyped using
the SequenomH MassARRAY technology (SequenomH; San
Diego, CA, USA). Additionally one SNP was genotyped in a
larger sample size using TaqMan Single Nucleotide Polymorphism
(SNP) Genotyping Assay (Applied Bio systems). SNP-specific
primers and probes were designed and assays were performed
according to the manufacturer’s instructions.
Supporting Information
Table S1 Region-specific primers for amplification of 16 exons
in the Nicastrin gene.
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Western European samples’’ are from the MRC cohort, and the Addneuromed study. The UK samples comprise of individuals recruited from centres in London and
Cardiff, and the ‘‘Other Western Europeans’’ from centres in Italy, Poland, France and Finland (see methods and references for more details).
doi:10.1371/journal.pone.0017298.t003
Nicastrin Risk Variants for Alzheimer’s Disease
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17298
Author Contributions
Conceived and designed the experiments: MKL JFP. Performed the
experiments: MKL PP. Analyzed the data: MKL PP RW. Contributed
reagents/materials/analysis tools: MD MT GH MP KL BMM IK HS PM
BV DH PH SL. Wrote the manuscript: MKL JFP.
References
1. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009)
Genome-wide association study identifies variants at CLU and PICALM
associated with Alzheimer’s disease. Nat Genet 41: 1088–1093.
2. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-
wide association study identifies variants at CLU and CR1 associated with
Alzheimer’s disease. Nat Genet 41: 1094–1099.
3. Mitsui J, Fukuda Y, Azuma K, Tozaki H, Ishiura H, et al. (2010) Multiplexed
resequencing analysis to identify rare variants in pooled DNA with barcode
indexing using next-generation sequencer. J Hum Genet 55: 448–455.
4. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, et al. (2009)
Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease.
N Engl J Med 361: 1651–1661.
5. Butler AW, Ng MY, Hamshere ML, Forabosco P, Wroe R, et al. (2009) Meta-
analysis of linkage studies for Alzheimer’s disease–a web resource. Neurobiol
Aging 30: 1037–1047.
6. Dries DR, Yu G (2008) Assembly, maturation, and trafficking of the gamma-
secretase complex in Alzheimer’s disease. Curr Alzheimer Res 5: 132–146.
7. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, et al. (1995)
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus.
Science 269: 973–977.
8. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, et al. (1995)
Familial Alzheimer’s disease in kindreds with missense mutations in a gene on
chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376: 775–778.
9. Yu G, Nishimura M, Arawaka S, Levitan D, Zhang L, et al. (2000) Nicastrin
modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP
processing. Nature 407: 48–54.
10. Dermaut B, Theuns J, Sleegers K, Hasegawa H, Van den BM, et al. (2002) The
gene encoding nicastrin, a major gamma-secretase component, modifies risk for
familial early-onset Alzheimer disease in a Dutch population-based sample.
Am J Hum Genet 70: 1568–1574.
11. Cousin E, Hannequin D, Mace S, Dubois B, Ricard S, et al. (2003) No
replication of the association between the Nicastrin gene and familial early-onset
Alzheimer’s disease. Neurosci Lett 353: 153–155.
12. Helisalmi S, Dermaut B, Hiltunen M, Mannermaa A, Van den BM, et al. (2004)
Possible association of nicastrin polymorphisms and Alzheimer disease in the
Finnish population. Neurology 63: 173–175.
13. Deary IJ, Hamilton G, Hayward C, Whalley LJ, Powell J, et al. (2005) Nicastrin
gene polymorphisms, cognitive ability level and cognitive ageing. Neurosci Lett
373: 110–114.
14. Ma Z, Han D, Zuo X, Wang F, Jia J (2009) Association between promoter
polymorphisms of the nicastrin gene and sporadic Alzheimer’s disease in North
Chinese Han population. Neurosci Lett 458: 136–139.
15. Orlacchio A, Kawarai T, Polidoro M, Paterson AD, Rogaeva E, et al. (2004)
Lack of association between Alzheimer’s disease and the promoter region
polymorphisms of the nicastrin gene. Neurosci Lett 363: 49–53.
16. Zhong L, Dong-hai Q, Hong-ying L, Qing-feng L (2009) Analysis of the
nicastrin promoter rs10752637 polymorphism and its association with
Alzheimer’s disease. Eur J Neurosci 30: 1831–1836.
17. Confaloni A, Terreni L, Piscopo P, Crestini A, Campeggi LM, et al. (2003)
Nicastrin gene in familial and sporadic Alzheimer’s disease. Neurosci Lett 353:
61–65.
18. Wang B, Yang W, Wen W, Sun J, Su B, et al. (2010) Gamma-secretase gene
mutations in familial acne inversa. Science 330: 1065.
19. Sunyaev S, Ramensky V, Koch I, Lathe W, III, Kondrashov AS, et al. (2001)
Prediction of deleterious human alleles. Hum Mol Genet 10: 591–597.
20. Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, et al. (2009)
Quantification of rare allelic variants from pooled genomic DNA. Nat Methods
6: 263–265.
21. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants of
IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes.
Science 324: 387–389.
22. Out AA, van Minderhout IJ, Goeman JJ, Ariyurek Y, Ossowski S, et al. (2009)
Deep sequencing to reveal new variants in pooled DNA samples. Hum Mutat
30: 1703–1712.
23. Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, et al. (2008)
Identification of genetic variants using bar-coded multiplexed sequencing. Nat
Methods 5: 887–893.
24. Cronn R, Liston A, Parks M, Gernandt DS, Shen R, et al. (2008) Multiplex
sequencing of plant chloroplast genomes using Solexa sequencing-by-synthesis
technology. Nucleic Acids Res 36: e122.
25. Erlich Y, Chang K, Gordon A, Ronen R, Navon O, et al. (2009) DNA Sudoku–
harnessing high-throughput sequencing for multiplexed specimen analysis.
Genome Res 19: 1243–1253.
26. Prabhu S, Pe’er I (2009) Overlapping pools for high-throughput targeted
resequencing. Genome Res 19: 1254–1261.
27. Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, et al. (2009)
Quantification of rare allelic variants from pooled genomic DNA. Nat Methods
6: 263–265.
28. Wang T, Lin CY, Rohan TE, Ye K (2010) Resequencing of pooled DNA for
detecting disease associations with rare variants. Genet Epidemiol 34: 492–501.
29. Bansal V (2010) A statistical method for the detection of variants from next-
generation resequencing of DNA pools. Bioinformatics 26: i318–i324.
30. Koboldt DC, Chen K, Wylie T, Larson DE, McLellan MD, et al. (2009)
VarScan: variant detection in massively parallel sequencing of individual and
pooled samples. Bioinformatics 25: 2283–2285.
31. Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, et al. (2005) Nicastrin functions as
a gamma-secretase-substrate receptor. Cell 122: 435–447.
32. Folstein MF, Folstein SE, McHugh PR (1975) ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician. J Psychiatr
Res 12: 189–198.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services Task
Force on Alzheimer’s Disease. Neurology 34: 939–944.
34. Abramoff MD, Magelhaes PJ, Ram SJ (2004) Image Processing with ImageJ.
Biophotonics International 11: 36–42.
35. Lovestone S, Francis P, Kloszewska I, Mecocci P, Simmons A, et al.
AddNeuroMed–the European collaboration for the discovery of novel
biomarkers for Alzheimer’s disease. Ann N Y Acad Sci 1180: 36–46.
36. Proitsi P, Hamilton G, Tsolaki M, Lupton M, Daniilidou M, et al. (2009) A
Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and
Psychological Symptoms in Dementia (BPSD). Neurobiol Aging.
37. Li H, Ruan J, Durbin R (2008) Mapping short DNA sequencing reads and
calling variants using mapping quality scores. Genome Res 18: 1851–1858.
Nicastrin Risk Variants for Alzheimer’s Disease
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17298
